Quanticate Launches Next Generation Functional Service Provision


Company News Release

With extensive experience in supporting Functional Service Provision (FSP) partnerships to the pharmaceutical, biotechnology, nutrition and device industries, Quanticate, a leading global data-focused clinical research organization (CRO) unveiled its next generation service to support customers through integrating centralization across functions.

“Centralized Service Provision (CSP), developed in collaboration with our clients, looks across functions to maximize the data being produced throughout drug, device and nutritional product development,” explained Daniel Chapple, Chief Commercial Officer at Quanticate.  “Our objective is to leverage the benefits of functional outsourcing and the efficiencies resulting from combining certain tasks across functions including data management, biostatistics, programming, medical writing and pharmacovigilance.” Chapple continued, “Creating innovation that fits with the objectives of pharmaceutical companies is important in today’s current climate, which is why we continually look to leverage our expertise in small and large-scale outsourcing partnerships to offer transformational solutions that meet the needs of our customers and partners.  Our objective has been to put in place an approach that provides benefits for all companies, regardless of size.”

With the recent launch of the “CliQ” centralization and visualization tool at Quanticate along with global expansion such as in India, CSP offers efficiencies at a study level whilst providing real operational advantages from individual drug developments through to large scale product portfolios.  Collecting the right data and using the best study design in a technology that enables standardization - regardless of source - is important in ensuring the integrity of conclusions through appropriate analysis and reporting. 

Yvonne Moores, Executive VP of the Strategic Resource Business Unit and who manages operations for Quanticate’s FSP partnerships explains, “To effectively visualize real-time data within and across trials is enabling organizations to optimize trial designs and gain a competitive advantage when drugs are launched. Technology comprises only part of the solution though.  Having experts who understand bio-statistical approaches such as Bayesian methodologies or adaptive designs, together with experts who can understand the implications of a decision later in the drug development life-cycle are also important elements to more effectively designed trials.”  Moores continues “Ensuring data standardization from the out-set can minimize data mapping, prevent delays at a later stage and help companies to quickly reach decision points or provide additional information that can be used to help market the product more effectively.  The use of the right talent in the most appropriate global locations is also important to ensure a cost effective, but high quality, approach.”

Additional information regarding CSP, CliQ and Quanticate services are available on the new company website just launched this June.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.